Phosphorylation of Ume6p in vivo. (A) Mobilities of wild-type and mutant Ume6p derivatives. Strain YX423 carrying integrated UME6 plasmids was grown in rich glucose medium (D; lanes 1, 4, 7, 10, 13, 16, and 19), rich acetate medium (Ac; lanes 2, 5, 8, 11, 14, 17, and 20), or acetate medium lacking nitrogen (sporulation medium [Sp]; lanes 3, 6, 9, 12, 15, 18, and 21). Migration of Ume6-HAp on SDS-PAGE was visualized on an anti-HA immunoblot. The UME6 plasmids specified Ume6p (lanes 1 to 3), wild-type Ume6-HAp (lanes 4 to 6), or mutant Ume6-HAp derivatives with substitutions specified above each set of three lanes (lanes 7 to 21). (B) Phosphatase treatment of Ume6-HAp. Anti-HA immune complexes were prepared from strain YX423 carrying a plasmid specifying Ume6-HAp and grown in rich glucose medium (lanes 1 to 4), rich acetate medium (lanes 5 to 8), or acetate medium lacking nitrogen (lanes 9 to 12). Migration of Ume6-HAp on SDS-PAGE was visualized on an anti-HA immunoblot. Prior to SDS-PAGE, the immune complexes were untreated (lanes 1, 5, and 9) or incubated at 37°C with no addition (lanes 2, 6, and 10), with phosphatase (lanes 3, 7, and 11), or with phosphatase plus phosphatase inhibitors (lanes 4, 8, and 12). (C) Effect of GSK3 homolog defects on Ume6-HAp mobility. SDS-PAGE mobility of Ume6-HAp was examined on an immunoblot of strains YX423 (wild type; lanes 1 to 3), YX425 (rim11; lanes 4 to 6), YX426 (mck1; lanes 7 to 9), YX427 (mrk1; lanes 10 to 12), YX428 (rim11 mck1; lanes 13 to 15), YX429 (mck1 mrk1; lanes 16 to 18), YX431 (rim11 mrk1; lanes 19 to 21), and YX424 (rim11 mck1 mrk1; lanes 22 to 24). Growth conditions and symbols are as in panel A. Sizes are indicated in kilodaltons.